HANSA BIOPHARMA

Hitto Kaufmann, Chief R&D Officer

June 2024



Hansa Biopharma – a biotech to believe in

Commercial stage, science driven biotechnology company in Sweden with financing through 2026

At a Glance

- **2007** founded in Lund
- **160** employees globally
- **$170M** market cap
- **$34.6M** recent financing round

Purpose driven Culture

- **33** different nationalities
- **4th year** Great Place to Work® certified
- **18%** reduction in energy consumption*

Proprietary technology platform

Autoimmune

Gene Therapy

Transplantation

PORTFOLIO

IMLIFIDASE
1st in class IgG cleaving molecule

HNSA-5487
Next-gen IgG cleaving molecule

PIPELINE

Two Phase 1
✓ 5487 FIH, DMD gene therapy

Three Phase 2
✓ AMR, GBS, ANCA (IIT)

Three Phase 3
✓ US kidney, EU post approval, anti-GBM

*according to 2023 Sustainability Report

Imlifidase: an innovative, first in class molecule with a novel approach to eliminate pathogenic IgG

Originates from a bacteria
Streptococcus pyogenes known from causing a strep throat infection

IgG antibody-cleaving enzyme
Interacts with Fc-part of IgG with extremely high specificity

Inactivates IgG in 2-6 hours
Rapid onset of action that inactivates IgG below detectable level in 2-6 hours

Unique MOA cleaves IgG creating an IgG free window for approximately one week



*The 5-year data is a continuation of the analysis at 3-years of crossmatch positive patients published in the *American Journal of Transplanta*

Inactivates IgG in 2-6 hours creating an IgG free window



First & only treatment approved for desensitization

EU Approval**
in kidney TX as IDEFIRIX®

75%
access in the EU transplant market

2025
planned US BLA filing; US trial ongoing

*IDEFIRIX approved in EEA under conditional approval for kidney transplantation

7 clinical trials in key disease areas

Autoimmune | Gene Therapy | Transplantation

HNSA-5487: a next gen enzyme with long and short interval redosing potential

Lower immunogenicity
could apply to diseases where prolonged or intermittent IgG free window is needed

Short interval redosing
create a longer IgG-low period

Long interval redosing
keeps IgG at a low level, potentially leading to greater efficacy vs monotherapy

Encouraging high level Ph 1 study results

single ascending dose in 36 healthy volunteers

- Administration was safe and well tolerated
- Fast and complete cleavage of IgG; PK in line with expectations
- Further analysis and lead indication selection completed in 2024

Potential indication landscape

through two different redosing regimens



Broad clinical pipeline in autoimmune, gene therapy and transplantation



[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

TRANSPLANTATION



Imlifidase may enable incompatible kidney Tx in highly sensitized patients

100k*	**DSAs**	**SOC**	**10-15%**
patients waiting for a kidney transplant	Donor specific antibodies that reject organ transplantation	based on organ compatibility	patients with DSAs – or highly sensitized - unlikely to be transplanted due to incompatibility

**In the US

Long term data in kidney transplantation confirms sustained benefit of imlifidase



- 82% five-year graft survival
- 90% patient survival rate
- 50 ml/min/m2 eGFR

EU Approval** as desensitization treatment as IDEFIRIX®

Addresses the limitations of other modalities

The **first and only** approved drug to enable incompatible kidney transplants

Market access in 75% of the EU transplant market

**IDEFIRIX approved in EEA under conditional approval for kidney transplantation

AUTOIMMUNE



Imlifidase may have relevance in several autoimmune diseases where IgG plays an important role in the pathogenesis

+100 autoimmune diseases

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin disorders
- Blood disorders

Imlifidase rapidly cleaves autoantibodies to stop disease progression in monophasic conditions

Proof of concept in two indications

Anti-GBM disease

1.6 in a million affected annually

Imlifidase Ph. 2 results

67% of patients were dialysis independent after six months vs. the historical cohort, where **only 18%** had functioning kidney

Phase 3 ongoing
50% enrolled

Guillain-Barré Syndrome

1.7-4.3 per 100,000 annually

Imlifidase Ph. 2 results

Rapid improvement across several efficacy outcome measures, as compared with previously published data

Phase 3 plans under review

Next-gen enzyme could provide novel treatment options of acute flairs in chronic conditions through redosing



Short interval redosing

Potential to **rapidly reverse autoimmune attack** through longer IgG-low window



Longer intervals redosing

HNSA-5487 quickly removes IgG – chronic immune inhibition adds to duration of effect

GENE THERAPY



Imlifdase may enable gene therapy treatment in rare disease patients with pre-existing antibodies

AAVs
the delivery system of gene therapy

5-70%
patients considered for gene therapy have anti-AAV antibodies

Pre-existing antibodies
excludes patients from trials & treatment

Eliminate antibodies as a pre-treatment to enable gene therapy



- **Significant unmet need**
- **Encouraging pre-clinical data**
- **Partnership strategy**

Global partnerships with gene therapy companies

SAREPTA THERAPEUTICS

- World leader within gene therapy targeted at muscular dystrophies
- High level read out in DMD expected 2024

AskBio

- Early innovator in gene therapy
- Encouraging Ph 1 data presented at ASGCT 2024

GENETHON
CURE THROUGH INNOVATION

- A not-for-profit pioneer in gene therapies
- Preclinical work underway in Crigler Najjar syndrome

Key milestones over the next 18-24 months

2024

AUTOIMMUNE

GBS Phase 2: Outcome of comparative efficacy analysis

GENE THERAPY

DMD Phase 1B: High level data read-out (Sarepta)
Crigler-Najjar Phase 1: Trial initiation (Genethon)

TRANSPLANTATION

Kidney TX US Phase 3: Randomization completed May 2024
AMR: publication in peer-reviewed journal

EARLY DEVELOPMENT

HNSA-5487: Further analysis and lead indication identified

2025

AUTOIMMUNE

Anti-GBM Phase 3: Complete enrolment
ANCA: Complete enrolment

TRANSPLANTATION

Kidney TX US: BLA submission
Kidney TX EU: Post approval study complete


HANSA
BIOPHARMA